

# RENOVA® IS THE ONLY BRANDED TRETINOIN INDICATED FOR FINE FACIAL WRINKLES


## WHEN USED AS PART OF A COMPREHENSIVE SKIN-CARE AND SUN AVOIDANCE REGIMEN

From Ortho Dermatologics, Renova (tretinoin cream) 0.02% is a dermatologist-prescribed product that has been clinically proven to help reduce the appearance of fine facial wrinkles.<sup>1</sup>

Renova works to diminish fine facial wrinkles by activating Vitamin A acid receptors below the skin's surface and encouraging cellular turnover. Renova visibly improves the appearance of the skin when used as part of a comprehensive skin-care regimen including sun avoidance and the use of a sunscreen with SPF 15 or higher.<sup>1,2</sup>

BEFORE

AFTER



Actual patient. Individual results may vary.

All photographs are completely unretouched. Results are after 24 weeks of treatment with Renova 0.02% and a comprehensive skin-care program including sun protection.



### Indication

RENOVA® (tretinoin cream) 0.02% is indicated as an adjunctive agent for use in the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin-care and sunlight-avoidance programs. RENOVA DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, OR RESTORE MORE YOUTHFUL OR YOUNGER SKIN.

The safety and efficacy of using RENOVA 0.02% have not been established:

- for mitigation of significant signs of chronic sun exposure such as coarse or deep wrinkling
- for daily use beyond 12 months, or
- for the prevention or treatment of actinic keratoses or skin neoplasms

### Important Safety Information

#### Contraindications

- RENOVA is contraindicated in individuals with a history of sensitivity reactions to any of its ingredients and should be discontinued if a reaction occurs.

**Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.**

**RENOVA®**  
(TRETINOIN CREAM)  
0.02%

## Important Safety Information (cont'd)

### Warnings and Precautions

- RENOVA 0.02% is a dermal irritant, and the results of continued irritation of the skin for greater than 52 weeks in chronic use with RENOVA (tretinoin cream) 0.02% are not known.
- Do not use RENOVA 0.02% if the patient is taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the possibility of augmented phototoxicity.
- Exposure to sunlight (including sunlamps) should be avoided or minimized during use of RENOVA because of heightened sunburn susceptibility. Patients should be warned to use sunscreens (minimum SPF of 15) and protective clothing when using RENOVA. Patients with sunburn should be advised not to use RENOVA until fully recovered. Patients who may have considerable sun exposure, and those patients with inherent sensitivity to sunlight should exercise caution when using RENOVA and follow the precautions outlined in the Patient Package Insert.
- RENOVA is for topical use only and should be kept out of the eyes, mouth, angles of the nose, and mucous membranes. Topical use may cause severe local erythema, pruritus, burning, stinging, and peeling at the site of application. If the degree of local irritation warrants, patients should be directed to use less medication, decrease frequency of use, discontinue use temporarily, or discontinue use altogether.
- Tretinoin has been reported to cause severe irritation on eczematous skin and should be used only with caution in patients with this condition.
- RENOVA should not be used by women who are pregnant or may become pregnant. In nursing women, consider postponing treatment until nursing is completed.
- Safety and effectiveness in patients less than 18 and greater than 71 years of age have not been established.
- In clinical trials, most patients experienced one or more local reactions such as peeling, dry skin, burning, stinging, erythema, and pruritus. In 32% of all study patients, skin irritation was reported that was severe, led to temporary discontinuation of RENOVA, or led to use of a mild topical corticosteroid.
- About 4% of patients discontinued use due to adverse reactions.

**To report SUSPECTED ADVERSE REACTIONS contact Ortho Dermatologics at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit [fda.gov/medwatch](https://www.fda.gov/medwatch).**

**Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.**

#### References:

1. RENOVA. Prescribing Information. Ortho Dermatologics.
2. Data on File. Ortho Dermatologics, Bridgewater, NJ. August, 2025.